Iceland· IS-EU/1/20/1496/001
Oxlumo
A lumasiran product containing lumasiranum inn natríum, registered in Iceland by Alnylam Netherlands B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Lumasiran is registered in 12 of 19 countries.
Countries holding a registration under ATC A16AX18 (lumasiran), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Lumasiran · ATC A16AX18
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Lumasiranum INN natríum
- Manufacturer
- Alnylam Netherlands B.V.
- Country
- Iceland (IS)
- ATC code
- A16AX18
- ATC class
- Lumasiran
- Defined daily dose
- 2.3 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lumasiran in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandOxlumo 94.5 mg / 0.5 ml, InjektionslösungAlnylam Switzerland GmbH
- SpainOXLUMO 94,5 mg/0,5 ml SOLUCION INYECTABLEAlnylam Netherlands B.V.
- PolandOxlumoAlnylam Netherlands B.V.
- SwedenOxlumo 94,5 mg/0,5 ml Injektionsvätska, lösningAlnylam Netherlands B.V.
- CanadaOXLUMOALNYLAM NETHERLANDS B.V.
- FranceOXLUMO 94,5 mg/0,5mL, solution injectableALNYLAM NETHERLANDS (PAYS-BAS)
- United KingdomOxlumo 94.5mg/0.5ml solution for injection vialsAlnylam UK Ltd
- NetherlandsOxlumo 189 mg/ml, oplossing voor injectieAlnylam Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Oxlumo
- Norway · Oxlumo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2154260f-a272-4449-9ad8-6df73f9a26e2 GET /v1/drugs/2154260f-a272-4449-9ad8-6df73f9a26e2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "A16AX18",
"marketed": false,
"strength": "94,5 mg/0,5 ml",
"ma_number": "EU/1/20/1496/001",
"substance": "Lumasiranum INN natríum",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í nýrnasjúkdómum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "44154"
}See everything about lumasiran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.